Publications

See a complete PubMed list of publications by Paul Lapchak, PhD, FAHA.


Selected Key Publications

Lapchak PA. Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective. Expert Opin Investig Drugs. 2011 Jan;20(1):13-22. http://informahealthcare.com/doi/abs/10.1517/13543784.2011.542410.

Lapchak PA, Zhang JH. Resolving the negative data publication dilemma in translational stroke research. Transl Stroke Res. 2011 Mar 1;2(1):1-6. http://link.springer.com/article/10.1007%2Fs12975-010-0057-x.

Lapchak PA. Emerging therapies: pleiotropic multi-target drugs to treat stroke victims. Transl Stroke Res. 2011 Jun 1;2(2):129-135. http://link.springer.com/article/10.1007%2Fs12975-011-0074-4.

Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem. 2011 Jan;116(1):122-131. http://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2010.07090.x/abstract;jsessionid=B0B315E55B91D7A60B0281D5891DCA05.f04t02.

Lapchak PA. Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. Transl Stroke Res. 2013 Jun;4(3):328-342. http://link.springer.com/article/10.1007%2Fs12975-012-0200-y.

Lapchak PA, Doyan S, Fan X, Woods CM. Synergistic effect of AJW200, a von Willebrand factor neutralizing antibody with low dose (0.9 mg/mg) thrombolytic therapy following embolic stroke in rabbits. J Neurol Neurophysiol. 2013;4(2):146. http://omicsonline.org/neurology-neurophysiology-abstract.php?abstract_id=12391.

Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013 Mar;44(3):841-843. http://stroke.ahajournals.org/content/44/3/841.

Fagan SC, Lapchak PA, Liebeskind DS, Ishrat T, Ergul A. Recommendations for preclinical research in hemorrhagic transformation. Transl Stroke Res. 2013 Jun;4(3):322-327. http://link.springer.com/article/10.1007%2Fs12975-012-0222-5.

Lapchak PA. Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res. 2013 Dec;4(6):704-709. http://link.springer.com/article/10.1007%2Fs12975-013-0303-0.

Lapchak PA, Bombien R, Rajput PS. J-147 a novel hydrazide lead compound to treat neurodegeneration: CeeTox™ safety and genotoxicity. J Neurol Neurophysiol. 2013;4(3):154. http://omicsonline.org/J-147-a-novel-hydrazide-lead-compound-to-treat-neurodegeneration-ceetox-safety-and-genotoxicity-ana-2155-9562.1000158.php?aid=16182.

Lapchak PA, Boitano PD. Effect of the pleiotropic drug CNB-001 on tissue plasminogen activator (tPA) protease activity in vitro: support of combination therapy to treat acute ischemic stroke. J Neurol Neurophysiol 2014;5(4):214. http://omicsonline.org/neurology-neurophysiology-abstract.php?abstract_id=27503.

Lapchak PA, Lara J, Boitano PD. 4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl-)-1-phenyl-1H-pyrazoyl-3-yl) vinyl)-2-methoxy-phenol) (CNB-001) does not regulate human recombinant protein-tyrosine phosphatase1B (PTP1B) activity in vitro. J Neurol Neurophysiol. 2014;5(5):232. http://omicsonline.org/neurology-neurophysiology-abstract.php?abstract_id=30980.


Books

Lapchak PA, Zhang JH, eds. Translational Stroke Research: From Target Selection to Clinical Trials. New York, NY: Springer; 2012. (ISBN 978-1-4419-9529-2).

Android app on Google Play